Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-824X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia ; volume:4 ; number:1 ; day:5 ; month:7 ; year:2012 ; pages:1-7 ; date:12.2012
Vascular cell ; 4, Heft 1 (5.7.2012), 1-7, 12.2012
- Urheber
-
Govindarajan, Baskaran
Willoughby, Laura
Band, Hamid
Curatolo, Adam S.
Veledar, Emir
Chen, Suephy
Bonner, Michael Y.
Abel, Martin-Garrido
Moses, Marsha A.
Arbiser, Jack L.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/2045-824X-4-11
- URN
-
urn:nbn:de:101:1-2021082906554953543032
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Govindarajan, Baskaran
- Willoughby, Laura
- Band, Hamid
- Curatolo, Adam S.
- Veledar, Emir
- Chen, Suephy
- Bonner, Michael Y.
- Abel, Martin-Garrido
- Moses, Marsha A.
- Arbiser, Jack L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Optimization, Formulation, and Stability of Topical Rapamycin Used for Rare Tuberous Sclerosis Disease: from Ointment to Liposomes
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations
Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up
Intraepithelial neoplasia
Focal gigantism in tuberous sclerosis
Immunomodulation of neoplasia
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Optimization, Formulation, and Stability of Topical Rapamycin Used for Rare Tuberous Sclerosis Disease: from Ointment to Liposomes
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations
Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up
Intraepithelial neoplasia
Focal gigantism in tuberous sclerosis
Immunomodulation of neoplasia
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Optimization, Formulation, and Stability of Topical Rapamycin Used for Rare Tuberous Sclerosis Disease: from Ointment to Liposomes
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations
Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up
Intraepithelial neoplasia
Focal gigantism in tuberous sclerosis